We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

AnaptysBio Inc (ANAB) USD0.001

Sell:$23.92 Buy:$23.95 Change: $0.83 (3.32%)
NASDAQ:0.22%
Market closed |  Prices as at close on 21 May 2024 | Switch to live prices |
Sell:$23.92
Buy:$23.95
Change: $0.83 (3.32%)
Market closed |  Prices as at close on 21 May 2024 | Switch to live prices |
Sell:$23.92
Buy:$23.95
Change: $0.83 (3.32%)
Market closed |  Prices as at close on 21 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Contact details

Address:
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO
92121
United States
Telephone:
+1 (858) 3626295
Website:
https://www.anaptysbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ANAB
ISIN:
US0327241065
Market cap:
$683.24 million
Shares in issue:
27.32 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • John Orwin
    Chairman of the Board
  • Daniel Faga
    President, Chief Executive Officer, Director
  • Dennis Mulroy
    Chief Financial Officer
  • Eric Loumeau
    Chief Operating Officer, General Counsel
  • Paul Lizzul
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.